GCATx focuses on developing small molecule drugs against genetically-defined high-value targets critical to disease mechanisms. A number of indications especially within oncology are driven by activating somatic mutations, providing highly validated targets for therapeutic intervention.
Our business model seeks to execute a scalable R&D and out-licensing strategy that minimizes scientific risk (rigorous target selection process) and development expense (working with reputable CROs).
The company has a proactive business development approach through seeking buy-in from potential industry partners in advance.
GCATx management team has extensive scientific, financial, business development, and strategic transaction experience within the Biopharma industry.
Our capital-efficient structure for drug discovery and development uniquely positions the company to create potential value for all stakeholders.
Our lead program is in development for Acute Lymphoblastic Leukemia (ALL), the most common pediatric cancer which accounts for greater than 25% of all childhood malignancies